Loading...
•
Mar 31, 2025
ACADIA Q1 2025 Earnings Report
Reported First Quarter 2025 Financial Results and Operating Overview
Key Takeaways
Acadia Pharmaceuticals reported a strong start to 2025 with total revenues of $244.3 million in the first quarter, representing a 19% year-over-year increase. Both NUPLAZID and DAYBUE product sales contributed to the growth, with NUPLAZID sales up 23% and DAYBUE sales up 11%. The company also highlighted progress in its pipeline, accelerating the timeline for the COMPASS PWS Phase 3 study results.
Total revenues for the first quarter of 2025 were $244.3 million, a 19% increase year-over-year.
NUPLAZID net product sales reached $159.7 million, growing 23% compared to the first quarter of 2024.
DAYBUE net product sales were $84.6 million, an 11% increase year-over-year, with unique patients shipped increasing by 9.5%.
The company accelerated the timeline for topline results from the COMPASS PWS Phase 3 study of ACP-101 to early in the fourth quarter of 2025.
Revenue by Segment
Forward Guidance
Acadia Pharmaceuticals reiterated its full year 2025 financial guidance, with an updated range for R&D expenses.
Positive Outlook
- Reiterates full year 2025 Total Revenues guidance range of $1.03 to $1.095 billion (U.S. only).
- Reiterates full year 2025 NUPLAZID net product sales guidance range of $650 to $690 million.
- Reiterates full year 2025 DAYBUE net product sales guidance range of $380 to $405 million (U.S. only).
- Accelerated timeline for COMPASS PWS Phase 3 study topline results to early Q4 2025.
- Anticipates submitting a New Drug Application for ACP-101 in Q1 2026 if Phase 3 results are positive.
Challenges Ahead
- Increased full year 2025 R&D expense guidance range to $330 to $350 million (up from $310 to $330 million).
- Full year 2025 SG&A expense guidance range of $535 to $565 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...